|
Volumn 61, Issue 8, 2002, Pages 723-725
|
Anti-tumour necrosis factor (TNF) α treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13
|
Author keywords
[No Author keywords available]
|
Indexed keywords
C REACTIVE PROTEIN;
INFLIXIMAB;
INTERLEUKIN 12;
INTERLEUKIN 13;
INTERLEUKIN 18;
RHEUMATOID FACTOR;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR ALPHA RECEPTOR;
ANTIRHEUMATIC AGENT;
MONOCLONAL ANTIBODY;
ADULT;
ARTICLE;
CLINICAL ARTICLE;
DOWN REGULATION;
ENZYME LINKED IMMUNOSORBENT ASSAY;
ERYTHROCYTE SEDIMENTATION RATE;
FEMALE;
HUMAN;
INFUSION;
MALE;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
TH1 CELL;
TH2 CELL;
METABOLISM;
MIDDLE AGED;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
DOWN-REGULATION;
FEMALE;
HUMAN;
INTERLEUKIN-12;
INTERLEUKIN-13;
INTERLEUKIN-18;
MALE;
MIDDLE AGE;
HUMANS;
MIDDLE AGED;
|
EID: 0035997487
PISSN: 00034967
EISSN: None
Source Type: Journal
DOI: 10.1136/ard.61.8.723 Document Type: Article |
Times cited : (66)
|
References (17)
|